The Technical Analyst
Glaukos Corp [GKOS]
Exchange: NYSE Sector: Healthcare Industry: Medical Devices
Glaukos Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.71% $107.67
America/New_York / 9 mai 2024 @ 11:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 422.82 mill |
| EPS: | -2.88 |
| P/E: | -37.38 |
| Earnings Date: | Jul 31, 2024 |
| SharesOutstanding: | 50.37 mill |
| Avg Daily Volume: | 0.522 mill |
| RATING 2024-05-08 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -37.38 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -37.38 | industry: PE -41.13 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-22.70 (-121.09%) $-130.37 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 104.21 - 110.87 ( +/- 3.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-06 | Gilliam Joseph E | Buy | 105 | Common Stock |
| 2024-05-06 | Gilliam Joseph E | Sell | 105 | Common Stock |
| 2024-05-06 | Gilliam Joseph E | Sell | 105 | Stock Option (Right to Buy) |
| 2024-05-06 | Thurman Alex R. | Sell | 90 | Common Stock |
| 2024-05-02 | Thurman Alex R. | Sell | 335 | Common Stock |
| INSIDER POWER |
|---|
| 2.24 |
| Last 100 transactions |
| Buy: 486 944 | Sell: 467 038 |
Forecast:
13:17 - $107.56
Live Trading Signals (every 1 min)
Forecast
1: 11:47 - $107.59
Forecast 2: 12:37 - $107.65
Forecast 3: 13:17 - $107.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $107.67 (0.71% ) |
| Volume | 0.0327 mill |
| Avg. Vol. | 0.522 mill |
| % of Avg. Vol | 6.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GKOS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest Press Releases
2024-05-01 16:05:00 - Press Release
Glaukos Announces First Quarter 2024 Financial Results
Aliso viejo, calif.--(business wire)--glaukos corporation (nyse: gkos), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended march 31, 2024. key highlights include: record net sales of $85.6 million in q1 2024 increased 16% year-over-year. glaucoma record net sales of $67.2 million in q1 2024 increased 20% year-over-year. corneal.
2024-04-16 16:05:00 - Press Release
Glaukos Announces The Release Of Its 2023 Sustainability Report
Aliso viejo, calif.--(business wire)--glaukos corporation (nyse: gkos), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 sustainability report. the report highlights the company's continued commitment and progress on its key corporate sustainability initiatives. the sustainability report can be found on the company's website here. “i am prou.
2024-04-10 07:00:00 - Press Release
Glaukos To Release First Quarter 2024 Financial Results After Market Close On May 1
Aliso viejo, calif.--(business wire)--glaukos corporation (nyse: gkos), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on wednesday, may 1, 2024. the company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. pt (4:30 p.m. et) on may 1, 2024. a link to the live.
2024-04-03 07:00:00 - Press Release
Glaukos Receives Permanent J-code For Idose® Tr (travoprost Intracameral Implant)
Aliso viejo, calif.--(business wire)--glaukos corporation (nyse: gkos), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the u.s. centers for medicare and medicaid services (cms) has assigned a unique, permanent healthcare common procedure coding system (hcpcs) j-code for idose® tr (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reductio.
2024-02-21 16:05:00 - Press Release
Glaukos Announces Fourth Quarter And Full Year 2023 Financial Results
Aliso viejo, calif.--(business wire)--glaukos corporation (nyse: gkos), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended december 31, 2023. key highlights include: record net sales of $82.4 million in q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. gl.
Latest News
2024-05-02 10:16:13 - Zacks Investment Research
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.
2024-05-01 20:42:08 - Seeking Alpha
Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Chris Lewis - Vice President of IR & Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Matt O'Brien - Piper Sandler George Sellers - Stephens Allen Gong - JPMorgan Joanne Wuensch - Citigroup Margaret Kaczor - William Blair David Saxon - Needham Sam Brodovsky - Truist Securities Anthony Petrone - Mizuho Steve Lichtman - Oppenheimer & Company Michael Sarcone - Jefferies Operator Welcome to Glaukos Corporation's First Quarter 2024 Financial Results Conference Call...
2024-05-01 18:51:07 - Zacks Investment Research
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.59 per share a year ago.
2024-04-15 09:21:15 - Zacks Investment Research
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
2024-04-12 10:26:12 - Zacks Investment Research
Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
2024-04-08 11:46:03 - Zacks Investment Research
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
2024-04-04 13:05:24 - Zacks Investment Research
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
2024-03-13 09:01:10 - Zacks Investment Research
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
2024-02-22 10:00:47 - Zacks Investment Research
Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y
Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.
2024-02-21 23:13:02 - Seeking Alpha
Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript
